

### ACRad 36: Incidental Coronary Artery Calcification Reported on Chest CT

<b>Measure Description:</b>	Percentage of final reports for male patients aged 18 years through 50 and female patients aged 18 through 65 years undergoing noncardiac noncontrast chest CT exams or with and without contrast chest CT exams that note presence or absence of coronary artery calcification (CAC) or not evaluable
<b>Denominator:</b>	All final reports for male patients aged 18 years through 50 and female patients aged 18 through 65 years undergoing noncardiac noncontrast chest CT exams or with and without contrast chest CT exams
	<b>Denominator CPT Codes:</b> 71250, 71270, 71271
<b>Exclusions:</b>	Patients who received prior coronary artery bypass grafts or prior percutaneous coronary intervention with stent
<b>Numerator:</b>	Final reports that note presence or absence of coronary artery calcification or not evaluable
	<b>Performance Met (36XPM):</b> Final report indicates presence/absence/not evaluable of CAC. <b>Performance Not Met: (36XNM):</b> Final report does not include any mention of CAC.

### ACRad 37: Interpretation of CT Pulmonary Angiography (CTPA) for Pulmonary Embolism

<b>Measure Description:</b>	Percentage of final reports for patients aged 18 years and older undergoing CT pulmonary angiography (CTPA) with a finding of PE that specify the branching order level of the most proximal level of embolus (i.e. main, lobar, interlobar, segmental, sub segmental)
<b>Denominator:</b>	All final reports for patients aged 18 years and older undergoing CT pulmonary angiography (CTPA) with a finding of pulmonary embolism
	<b>Denominator CPT Codes:</b> 71275 <b>Secondary Denominator Info (ICD-10, finding of pulmonary embolism):</b> I26.01, I26.02, I26.09, I26.90, I26.92, I26.93, I26.94, I26.99, I27.82, O88.2, O08.2
<b>Exclusions:</b>	None
<b>Numerator:</b>	Final reports that specify that branching order level of the most proximal level of embolus (i.e. main, lobar, interlobar, segmental, subsegmental)
	<b>Performance Met (37XPM):</b> Final report specifies branching order level of the most proximal level of embolus. <b>Performance Not Met: (37XNM):</b> Final report does not specify branching order of the most proximal level of embolus.

**ACRad 38: Use of Low Dose Cranial CT or MRI Examinations for Patients with Ventricular Shunts**

<b>Measure Description:</b>	Percentage of patients aged less than 18 years with a ventricular shunt undergoing cranial imaging exams to evaluate for ventricular shunt malfunction undergoing either low dose cranial CT exams or MRI
<b>Denominator:</b>	All patients aged less than 18 years with a ventricular shunt undergoing cranial imaging exams to evaluate for ventricular shunt malfunction
	<b>Denominator CPT Codes:</b> 70450, 70460, 70470, 70496, 70551, 70552, 70553 <b>Secondary Denominator Info (Evaluation for ventricular shunt malfunction):</b> DX038
<b>Exclusions:</b>	Patients with an active diagnosis or history of cancer; Patients with a diagnosis of meningitis; Trauma patients
<b>Numerator:</b>	Patients undergoing either low dose cranial CT exams or MRI  <b>Note:</b> For this measure, “low-dose cranial CT” is defined as dose length product (DLP) <300 mGy for patients aged 2 years and younger; DLP <405 for patients aged 3 through 6; DLP <492 for patients aged 7 through 10, DLP <604 for patients aged 11 through 14, and DLP <739 for patients aged 15 and up.
	<b>Performance Met (38XPM):</b> Patient is undergoing either low-dose CT or MRI. <b>Performance Not Met: (38XNM):</b> Patients is not undergoing either low-dose CT or MRI.

**ACRad 39: Use of Low Dose CT Studies for Adults with Suspicion of Urolithiasis or Nephrolithiasis**

<b>Measure Description:</b>	Percentage of patients aged 18 years and older with a diagnosis of urolithiasis or nephrolithiasis undergoing CT imaging exams of the abdomen or pelvis to evaluate for urologic stones undergoing only low-dose CT exams of the abdomen or pelvis without intravenous contrast
<b>Denominator:</b>	All patients aged 18 years and older with a diagnosis of urolithiasis or nephrolithiasis undergoing CT exams of the abdomen or pelvis without intravenous contrast to evaluate for urologic stones
	<b>Denominator CPT Codes:</b> 72192, 72194, 74150, 74170, 74176, 74178 <b>Secondary Denominator Info (ICD-10, urologic stone evaluation):</b> DX039
<b>Exclusions:</b>	Patients with a BMI of >35 or equivalent (i.e. waist circumference >88cm in women and >102cm in men)
<b>Numerator:</b>	Patients undergoing only low-dose CT exams of the abdomen or pelvis  <b>Note:</b> For this measure, “low-dose CT” is defined as DLP <650 mGy
	<b>Performance Met (39XPM):</b> Patient is undergoing only low-dose CT of the abdomen or pelvis. <b>Performance Not Met: (39XNM):</b> Patient is not undergoing only low-dose CT of the abdomen or pelvis.

#### ACRad 40: Use of Structured Reporting in Prostate MRI

<b>Measure Description:</b>	Percentage of final reports for male patients aged 18 years and older undergoing prostate MRI for prostate cancer screening or surveillance that include reference to a validated scoring system such as Prostate Imaging Reporting and Data System (PI-RADS)
<b>Denominator:</b>	All final reports for male patients aged 18 years and older undergoing prostate MRI for prostate cancer screening or surveillance
	<b>Denominator CPT Codes:</b> 72195, 72196, 72197, 72198 <b>Secondary Denominator Info (Prostate screening or surveillance):</b> DX040
<b>Exclusions:</b>	None
<b>Numerator:</b>	Final reports that include reference to a validated scoring system such as Prostate Imaging Reporting and Data System (PI-RADS)
	<b>Performance Met (40XPM):</b> Final report includes reference to PI-RADS or other scoring system. <b>Performance Not Met: (40XNM):</b> Final report does not include reference to PI-RADS or other scoring system.

#### ACRad 41: Use of Quantitative Criteria for Oncologic FDG PET Imaging

<b>Measure Description:</b>	Percentage of final reports for all patients, regardless of age, undergoing non-CNS oncologic FDG PET studies that include at a minimum: a. Serum glucose (e.g. finger stick at time of injection) b. Uptake time (interval from injection to initiation of imaging) c. One reference background (e.g. volumetric normal liver or mediastinal blood pool) SUV measurement, along with description of the SUV measurement type (e.g. SUVmax) and normalization method (e.g. BMI) d. At least one lesional SUV measurement OR diagnosis of "no disease-specific abnormal uptake"
<b>Denominator:</b>	All final reports for all patients, regardless of age, undergoing non-CNS oncologic FDG PET studies
	<b>Denominator CPT Codes:</b> 78811, 78812, 78813, 78814, 78815, 78816, G0219, G0235 <b>Secondary Denominator Info (Oncologic study using FDG radiopharmaceutical):</b> DX041
<b>Exclusions:</b>	None
<b>Numerator:</b>	Final reports for FDG PET scans that include at a minimum elements a. through d. listed above.
	<b>Performance Met (41XPM):</b> Final report includes at a minimum elements a. through d. above. <b>Performance Not Met: (41XNM):</b> Final report does not include elements a. through d.

**ACRad 42: Surveillance Imaging for Liver Nodules <10mm in Patients at Risk for Hepatocellular Carcinoma (HCC)**

<b>Measure Description:</b>	Percentage of final ultrasound reports with findings of liver nodules < 10 mm for patients aged 18 years and older with a diagnosis of hepatitis B or cirrhosis undergoing screening and/or surveillance imaging for hepatocellular carcinoma with a specific recommendation for follow-up ultrasound imaging in 3-6 months based on radiological findings
<b>Denominator:</b>	All final ultrasound reports with findings of liver nodules < 1 cm for patients aged 18 years and older with a diagnosis of hepatitis B or cirrhosis undergoing screening and/or surveillance imaging for hepatocellular carcinoma
	<p><b>Denominator CPT Codes:</b> 76700, 76705, 76981, 76982</p> <p><b>Secondary Denominator Info (ICD-10, diagnosis of cirrhosis or hepatitis B):</b> K74.60, K74.69, B16, B17.0, B18.0, B18.1, B19.1, B19.10, B19.11, K76.9, K70.3, K70.30, K70.31</p> <p style="text-align: center;"><b><u>AND</u></b></p> <p><b>Secondary Denominator Info (Finding of liver nodule &lt;1.0cm):</b> DX042</p> <p><i>(Example: K74.60 &amp; DX042)</i></p>
<b>Exclusions:</b>	Patients with an active diagnosis or history of cancer
<b>Numerator:</b>	Final ultrasound reports with a specific recommendation for follow-up ultrasound imaging in 3-6 months
	<p><b>Performance Met (42XPM):</b> Final report includes specific recommendation for follow-up ultrasound imaging in 3-6 months.</p> <p><b>Performance Not Met: (42XNM):</b> Final report does not include specific recommendation for follow-up ultrasound imaging in 3-6 months.</p>